Entrada Therapeutics (TRDA) Other Gross PP&E Adjustments (2022 - 2025)
Entrada Therapeutics (TRDA) has 4 years of Other Gross PP&E Adjustments data on record, last reported at -$46.4 million in Q4 2025.
- For Q4 2025, Other Gross PP&E Adjustments rose 12.81% year-over-year to -$46.4 million; the TTM value through Dec 2025 reached -$46.4 million, up 12.81%, while the annual FY2025 figure was -$46.4 million, 12.81% up from the prior year.
- Other Gross PP&E Adjustments reached -$46.4 million in Q4 2025 per TRDA's latest filing, down from -$43.5 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$1.0 million in Q1 2023 and bottomed at -$72.9 million in Q2 2023.
- Average Other Gross PP&E Adjustments over 4 years is -$43.2 million, with a median of -$46.9 million recorded in 2025.
- Peak YoY movement for Other Gross PP&E Adjustments: surged 95.48% in 2023, then crashed 5942.55% in 2024.
- A 4-year view of Other Gross PP&E Adjustments shows it stood at -$15.5 million in 2022, then plummeted by 327.26% to -$66.1 million in 2023, then grew by 19.52% to -$53.2 million in 2024, then rose by 12.81% to -$46.4 million in 2025.
- Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were -$46.4 million in Q4 2025, -$43.5 million in Q3 2025, and -$44.5 million in Q2 2025.